China National MedicinesSHSE:600511 +1.62%86 PB Ratio is 1.07 as of Jul. 04, 2026, which is 43% below its 10-year median of 1.89. GuruFocus rates SHSE:600511 with a GF Score™ of 86/100 and a GF Value™ of ¥32.74 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 110 Medical Distribution companies, China National Medicines ranks worse than 51.82% on this metric.
China National Medicines Corp Ltd stock PB Ratio (=1.07) is close to 10-year low of 1.02.
The historical rank and industry rank for China National Medicines's PB Ratio or its related term are showing as below:
SHSE:600511'
s PB Ratio Range Over the Past 10 Years
Min: 1.02 Med: 1.89 Max: 7.53
Current: 1.07
During the past 13 years, China National Medicines's highest PB Ratio was 7.53. The lowest was 1.02. And the median was 1.89.
SHSE:600511's PB Ratio is ranked worse than 51.82% of 110
companies
in the Medical Distribution industry
Industry Median: 1.02
vs SHSE:600511: 1.07
During the past 12 months, China National Medicines's average Book Value Per Share Growth Rate was 8.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 9.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 10.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 11.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of China National Medicines was 40.50% per year. The lowest was 4.60% per year. And the median was 19.90% per year.
Back to Basics: PB Ratio
China National Medicines (SHSE:600511) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, China National Medicines's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China National Medicines PB Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, China National Medicines's PB Ratio distribution charts can be found below:
* The bar in red indicates where China National Medicines's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
China National Medicines (SHSE:600511) has a PB Ratio of 1.07 as of Jul. 04, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on China National Medicines and its competitors. This is 43% below median its historical median of 1.89. Over the past decade, China National Medicines' PB Ratio has ranged from 1.02 to 7.53. According to the industry distribution chart, China National Medicines ranks #57 out of 110 companies in the Medical Distribution industry, placing it in the top 51.8%.
Is China National Medicines' PB Ratio too high?
China National Medicines' current PB Ratio of 1.07 is 43% below median its 10-year median of 1.89. Over the past 10 years, this metric has ranged from a low of 1.02 to a high of 7.53. The Medical Distribution industry median PB Ratio is 1.02. China National Medicines' value of 1.07 is 4.9% above this industry median. Based on the distribution chart, China National Medicines ranks #57 out of 110 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, China National Medicines has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China National Medicines' PB Ratio compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, China National Medicines ranks #57 out of 110 companies for PB Ratio. This places China National Medicines in the lower half of its industry. The industry median PB Ratio is 1.02. China National Medicines' value of 1.07 is 4.9% above this benchmark. Historically, China National Medicines' own PB Ratio has ranged from 1.02 to 7.53 over the past decade. While the company's 10-year median is 1.89 vs. the industry median of 1.02, China National Medicines has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Distribution company?
The median PB Ratio among Medical Distribution companies is 1.02, based on 110 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China National Medicines's current PB Ratio of 1.07 is 4.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on China National Medicines and its competitors. For the Medical Distribution industry, the median PB Ratio is 1.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China National Medicines's current PB Ratio is 1.07, which is 43% below median its own 10-year median of 1.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China National Medicines stock overvalued right now?
Based on GuruFocus' analysis, China National Medicines (SHSE:600511) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥32.74, compared to a current price of ¥26.94 — trading 17.7% below its estimated fair value. The current PB Ratio is 1.07, which is 43% below median its 10-year median of 1.89 and 4.9% above the Medical Distribution industry median of 1.02. China National Medicines' overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For China National Medicines (SHSE:600511), the current PB Ratio is 1.07 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China National Medicines (SHSE:600511) Overvalued in 2026?
Based on GuruFocus' analysis, China National Medicines stock appears to be undervalued.
The current stock price of ¥26.94 is trading 17.7% below its estimated GF Value™ of ¥32.74.
GuruFocus considers China National Medicines to be Modestly Undervalued.
Key valuation signals for SHSE:600511:
PB Ratio: 1.07 (43% below median its 10-year median of 1.89)
GF Value™: ¥32.74 vs. price of ¥26.94 (17.7% below fair value)
Industry Position: 4.9% above the Medical Distribution median (#57 of 110)
No single metric tells the full story. See the SHSE:600511 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China National Medicines Corp Ltd focuses on producing special drugs and high-end prescription drugs. Its main goal is to provide customers with professional medical services. The company conducts its operations through two primary segments. The Commercial segment is mainly engaged in the sale of pharmaceuticals. The Others segment focuses on pharmaceutical manufacturing and logistics operations.
86GF Score
Get the complete analysis for SHSE:600511
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600511 has been successfully added to your 
